Doximity, Inc. (DOCS) - 10-K Summary
Business Context and Reporting Period
Company: Doximity, Inc.
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal Year Ended March 31, 2025
Business Overview: Doximity is the leading digital platform for U.S. medical professionals, hosting over 2 million registered members, including more than 80% of U.S. physicians. The company generates revenue through Marketing Solutions (pharmaceutical and health system advertising), Hiring Solutions (recruiting), and Workflow Solutions (telehealth, scheduling, and AI tools).
Key Financial Metrics
| Metric (in millions) | Fiscal 2025 | Fiscal 2024 | Change |
|---|---|---|---|
| Revenue | $570.4 | $475.4 | +20% |
| Net Income | $223.2 | $147.6 | +51% |
| Adjusted EBITDA | $313.8 | $230.5 | +36% |
| Operating Cash Flow | $273.3 | $184.1 | +49% |
| Free Cash Flow | $266.7 | $178.3 | +50% |
| Gross Margin | 90% | 89% | +100 bps |
| Net Income Margin | 39% | 31% | +800 bps |
| Cash & Marketable Securities | $915.7 | $762.9 | N/A |
Debt & Liquidity: The company has no long-term debt. As of March 31, 2025, it held $915.7 million in cash, cash equivalents, and marketable securities. The company maintains a $500 million share repurchase program, with $424.0 million remaining available as of the period end.
Material Changes vs. Prior Period
- Revenue Growth: Driven primarily by a $93.7 million increase in subscription revenue. Expansion of existing customers contributed $83.3 million, while new customers added $10.4 million. Average revenue per existing Marketing Solutions customer increased by 22%.
- Profitability: Net income margin expanded significantly from 31% to 39%, and Adjusted EBITDA margin grew from 48% to 55%.
- Expense Management: Restructuring and impairment charges decreased by 71% to $2.3 million (down from $7.9 million in FY2024), primarily due to a one-time impairment charge related to a sublease in FY2025 versus a 10% workforce reduction in FY2024.
- Stock-Based Compensation: Increased to $72.4 million (from $51.1 million) due to new awards granted to new hires and existing employees.
- Other Income: Increased 68% to $35.8 million, driven by higher interest income on cash equivalents and marketable securities.
Guidance, Outlook, and Risks
Outlook & Strategy: Management expects to continue investing in R&D and sales/marketing to drive growth. Key strategies include expanding the network of medical professionals (currently under-penetrated among nurse practitioners and physician assistants), monetizing Workflow Solutions (specifically AI tools like Doximity GPT), and expanding within existing pharmaceutical and health system customers.
Risks & Contingencies:
- Legal Proceedings: The company is named in securities class action lawsuits and shareholder derivative lawsuits filed in April 2024 regarding disclosures of user counts and engagement rates. The company intends to defend vigorously but cannot predict the outcome.
- Customer Concentration: While no single customer accounted for 10% or more of revenue, revenue is relatively concentrated within a small number of key customers. Loss of a major customer could materially impact results.
- Regulatory Environment: Subject to stringent healthcare regulations (HIPAA, anti-kickback laws) and evolving data privacy laws. Changes in telehealth reimbursement policies could impact Workflow Solutions adoption.
- Competition: Faces competition from large tech companies (LinkedIn, Google) for members and specialized healthcare staffing/marketing firms for customers.
Investor Verification Checklist
- Legal Exposure: Monitor the status and potential financial impact of the securities litigation filed in April 2024 regarding user count disclosures.
- Customer Retention: Verify the sustainability of the 119% Net Revenue Retention Rate and the concentration risk among top customers.
- AI Monetization: Assess the adoption rates and revenue contribution of new AI-powered Workflow Solutions (Doximity GPT) to ensure they offset rising R&D costs.
- Share Repurchases: Track the execution of the remaining $424 million share repurchase authorization and its impact on earnings per share.
- Regulatory Changes: Watch for changes in federal or state telehealth reimbursement policies that could affect the growth of the Workflow Solutions segment.